Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 5/20 | 1.00 |
| ▸ | MAOA | P21397 | 8/20 | 0.74 |
| ▸ | MAOB | P27338 | 8/20 | 0.74 |
| ▸ | PRKCI | P41743 | 1/20 | 0.74 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030949 | 0.89 | HSD17B1 (1.00) | HSD17B1MAOAMAOBPRKCIPGR | |
| SCHEMBL228128 | 0.85 | MAOA (1.00) | HSD17B1MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL3021186 | 0.85 | HSD17B1 (0.74) | HSD17B1MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL7584101 | 0.84 | HSD17B1 (0.73) | HSD17B1MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL7506302 | 0.83 | HSD17B1 (0.71) | HSD17B1MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL8170785 | 0.83 | HSD17B1 (0.71) | HSD17B1MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL4418225 | 0.83 | HSD17B1 (0.71) | HSD17B1MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL3825921 | 0.82 | MAOA (0.92) | HSD17B1MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL7507255 | 0.81 | HSD17B1 (0.69) | HSD17B1MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL21222886 | 0.81 | HSD17B1 (0.68) | HSD17B1MAOAMAOBPRKCIPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| EP-2013176-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | Sterix Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| US-7067524-B2 | Substituted phenyl naphthalenes as estrogenic agents | WYETH (US) | 2006-06-27 | — | — | US | disclosed |
| CN-1738788-A | Substituted phenylnaphthalenes as estrogenic agents | WYETH CORP (US) | 2006-02-22 | — | — | CN | disclosed |
| US-6914074-B2 | Substituted phenyl naphthalenes as estrogenic agents | WYETH (US) | 2005-07-05 | — | — | US | disclosed |
| US-20040225123-A1 | Substituted phenyl naphthalenes as estrogenic agents | MEWSHAW RICHARD E (US) | 2004-11-11 | — | — | US | disclosed |
| EP-1453782-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | WYETH | 2003-09-25 | — | — | US | disclosed |
| WO-2003051805-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | ESR2, ESR1, ESRRA | HSD17B1 160/4885MAOA 4457/4885MAOB 4340/4885 |
| US-20090186900-A1 | COMPOUND | HSD17B2, HSD17B11, CYP17A1 | HSD17B1 4/4885MAOA 470/4885MAOB 494/4885 |
| US-20040225123-A1 | Substituted phenyl naphthalenes as estrogenic agents | ESR2, ESR1, ESRRA | HSD17B1 160/4885MAOA 4457/4885MAOB 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.